Highlights
- TGen appointed Nhan L. Tran, Ph.D., as Distinguished Professor and Vice President of Cancer Discovery and Translation, effective May 12, 2026.
- Tran returns to TGen after nearly a decade at Mayo Clinic, where he held joint appointments in Neurosurgery and Radiation Oncology.
- His lab will lead the Microbiome and Immuno-Oncology program, a joint effort spanning TGen, City of Hope, and Northern Arizona University.
- Tran's publication record includes more than 130 peer-reviewed articles and PI or co-PI roles on multiple National Cancer Institute-funded grants.
TGen, the Phoenix-based nonprofit biomedical research institute that is part of City of Hope, appointed Nhan L. Tran, Ph.D., to its faculty as Distinguished Professor, Vice President of Cancer Discovery and Translation, Co-director of its Immunology and Microbiome Division, and Scientific Director of the Microbiome and Immuno-Oncology (MIOC) program, according to a May 12, 2026, media release.
The MIOC program is a joint effort between TGen, City of Hope, and Northern Arizona University. Tran brings more than two decades of expertise in tumor biology, translational oncology, and the development of targeted therapies to the roles.
Tran returns to TGen after nearly a decade at Mayo Clinic, where he served as a Professor of Cancer Biology and held joint appointments in the Departments of Neurosurgery and Radiation Oncology. He began his career as an Associate Investigator at TGen following his postdoctoral work.
Who is Nhan L. Tran?
Tran is a glioblastoma researcher whose work centers on how tumor cells invade surrounding brain tissue and reshape their environment to evade the immune system. His publication record includes more than 130 peer-reviewed articles spanning cancer biology, imaging, molecular signaling, and precision medicine. He has served as PI or co-PI on numerous federally funded research grants, including National Cancer Institute-supported initiatives in mathematical oncology, tumor microenvironment modeling, and STAT5/OLIG2-mediated therapeutic resistance.
TGen President and Research Director Jeffrey M. Trent, Ph.D., said in the release that Tran is "a transformative scientist whose leadership and vision align perfectly with TGen's mission to rapidly move discoveries from the lab to the clinic."
Tran's Mayo Clinic faculty profile and his Google Scholar record confirm his prior institutional affiliations and publication history.
No financial terms or grant dollar amounts tied to the appointment were disclosed in the release. TGen's next public research update is expected through its City of Hope affiliate calendar.
Sources
Every factual claim in this article traces to one of the sources below. See how we work for the editorial process.
- tgen.org retrieved 14/05/2026 04:58
Authored by The Scottsdale Signal. Drafted by AI from primary-source material under our beat-specific editorial guides; reviewed by humans before publish under our five-gate process. Sources retrieved at 14/05/2026 04:58. Every claim traces to a source.
